clinical trial · NCT07009262
A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks
Hereditary AngioedemaInapplicable
brief summary
Patients with HAE Type I or II who enroll in the study are asked to complete a patient diary when they experience an HAE attack. If icatibant is taken as the first treatment for the attack, the patient diary will ask questions over a 48 hour period after dosing to track the characteristics and severity of the attack along with the patient's level of anxiety.
started
Apr 21, 2025
primary completion
Nov 25, 2025
completion
Nov 25, 2025
last updated
Jan 13, 2026
official title
A Prospective, Non-interventional Study in Patients With Type I or II Hereditary Angioedema Using Icatibant for On-demand Treatment of Attacks
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol